Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Several startups are raising interest—and dollars—to support innovative strategies for developing cell therapies to treat solid tumors. But their task is far from easy, with a combination of logistical hurdles and safety issues threatening to slow their progress.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
First patient receives “groundbreaking” treatment for cancer in Ireland
Oxford Biomedica plc has announced an extended commercial supply agreement with Novartis for the manufacture of lentiviral vectors for several Novartis CAR-T products.